Business Context and Reporting Period
Company: DexCom, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2026
Event: The company held its 2026 Investor Day in Mesa, Arizona, and announced a new share repurchase program.
Key Financial Metrics and Capital Allocation
This filing does not report historical revenue, profit, cash flow, or debt figures for a specific reporting period. Instead, it outlines long-term financial targets and a new capital allocation initiative:
- Share Repurchase Program: The Board authorized a new program to repurchase up to $1.0 billion of common stock, terminating the prior program which had $250.0 million remaining.
- Repurchase Period: The program is effective immediately and ends no later than June 30, 2027.
Material Changes and Long-Term Targets
During the Investor Day, DexCom announced new long-range financial targets for the year 2030. These represent a material update to the company's strategic outlook:
- Organic Revenue Growth: Target of 10%+ annually through 2030.
- Non-GAAP Gross Profit Margin (2030): 67% - 69%.
- Non-GAAP Operating Profit Margin (2030): 29% - 30%.
- Adjusted EBITDA Margin (2030): 36% - 37%.
Note: The filing states that reconciliations for these non-GAAP targets are not provided due to uncertainty regarding certain impacting items.
Guidance, Outlook, and Risks
Management Commentary: The company discussed market opportunities, business strategy, and innovation efforts. The new targets reflect management's confidence in long-term growth and margin expansion.
Forward-Looking Statements: The filing contains forward-looking statements regarding future operating results and financial position. Actual results may differ materially due to risks and uncertainties described in the company's most recent Form 10-K and Form 10-Q.
Share Repurchase Discretion: The company is not obligated to repurchase any specific amount of stock. The program may be extended, modified, suspended, or discontinued at any time based on market conditions.
Investor Verification Checklist
- Verify the definitions of the non-GAAP metrics (Organic Revenue, Adjusted EBITDA, etc.) in Exhibit 99.1 of the February 12, 2026 Form 8-K.
- Review the "Risk Factors" in the most recent Form 10-K to understand potential impediments to achieving the 2030 targets.
- Monitor future quarterly reports for actual execution of the $1.0 billion share repurchase program.
- Confirm that the $250.0 million remaining from the prior program was fully terminated and replaced by the new authorization.